您的瀏覽器不支援JavaScript功能，若網頁功能無法正常使用時，請開啟瀏覽器JavaScript狀態
跳到主要內容
:::

查詢icon列表(此標題會隱藏)

:::

視網膜病變團隊

團隊成員
視網膜團隊
研究成果

視網膜病變團隊

鄭幼文 教授

鄭幼文 教授

  • 團隊召集人

專長:

  • 毒性試驗、心血管藥理、基因毒性、抗血管新生、老人黃斑病變


     

TMU profile   Publications

蕭哲志 教授

蕭哲志 教授

專長:

  • 細胞訊息傳遞、抗MMP藥物之表觀與氧化還原調節機制、藥物開發 (發炎性眼與腦疾病)

 

 

 

TMU profile   Publications

曾靖孋 教授

曾靖孋 教授

專長:

  • 生醫材料、奈米藥物、組織工程



     

TMU profile   Publications

李青澔 副教授

李青澔 教授

專長:

  • 生理學、環境毒理學、奈米毒理學、安全藥理學、心血管生理學



     

TMU profile   Publications

何昭德 教授

何昭德 教授

專長:

  • 超小切口白內障超音波乳化手術、視網膜剝離(預防性與治療性雷射.鞏膜扣壓術.玻璃體切除術)、糖尿病視網膜病變(追蹤檢查.雷射.手術)、老年性黃斑部病變(新式光動力雷射治療.經瞳孔雷射熱治療)、高度近視網膜病變.各類視網膜疾病.葡萄膜炎、青光眼雷射治療、兒童視力保健

TMU profile   Publications

詹燕茹 博士後研究員

詹燕茹 博士後研究員

 

 

 

 

 

 

 

團隊成員順序依英文姓名排序

視網膜團隊

世界衛生組織近年來曾發布首份”世界視力報告”,指出人口老化、生活方式改變、眼科疾病照料不足以及藥物之缺乏是全球視力障礙人數不斷上升的主要因素。2020年全球眼藥市場約367億美金，預估到2028年將增加至600億美金。目前全球預估有1.1億人口有嚴重程度不同的眼睛相關疾病，可見不斷增加的眼科疾病未來將會是人類不可忽略的重大疾病。

本視網膜團隊主要研究方向包括，與視網膜相關的老人黃斑部病變、糖尿病誘發視網膜病變、青光眼及其致病機轉與風險因子。 此外還有、白內障、發炎性眼科疾病、眼腦疾病以及開發早期診斷眼腦相關疾病之生物標記與解決藥物通透與吸收不良的劑型改良等。

我們團隊包括臨床醫師, 生理、藥理、毒理、藥劑以及基礎神經科學研究人員, 我們獲得科技部補助，包括整合型與多項個人型計畫顯示專業與研究能力傑出且受到肯定。

我們期待, 整合各個研究團隊的能量, 能探究更多尚未明瞭的眼科疾病致病機轉以及針對人類最大的眼科疾病需求開發新的治療藥物。

發表文章

  • 1. Wu LH, Cheng YW, Lin FL, Hsu KC, Wang MH, Yen JL, Wang TJ, Lin TE, Liu YC, Huang W-J, Hsiao G, (2024) A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress. Biomed Pharmacother. (174):116538.
    2. Lin FL, Cheng YW*, Chen LH, Ho JD, Yen JL, Wang MH, Lee TH*, Hsiao G*, (2023). Retinal protection by fungal product Theissen lactone B in a sodium iodate-induced AMD model through targeting retinal pigment epithelial matrix metalloproteinase-9 and microglia activity. Biomedicine & Pharmacotherapy. (158):114138-114148.
    3. Chan YJ, Hsiao G, Wan WH, Tsa CH, Kang JJ, Lee YC, Fang TC, Cheng YW, Li CH, (2023). Blue light exposure collapses the inner blood-retinal barrier by accelerating endothelial CLDN5 degradation through the disturbance of GNAZ and the activation of ADAM17. Fluids and Barriers of the CNS. (20):1-20.
    4. Fitriana I, Wu GH, Hsu TJ, Chan YJ, Li CH, Lee CC, Hsiao G, Cheng YW, (2023). Activation of aryl hydrocarbon receptor by azatyrosine-phenylbutyric hydroxyamide inhibits progression of diabetic retinopathy mice. Biochemical Pharmacology. (1):1-13.
    5. Chan YJ, Liao PL, Tsai CH, Cheng YW, Lin FL, Ho JD, Chen CY, Li CH, (2021). Titanium dioxide nanoparticles impair the inner blood-retinal barrier and retinal electrophysiology through rapid ADAM17 activation and claudin-5 degradation. Particle and Fibre Toxicology. (18):1-16.
    6. Hsu TJ, Nepali, K, Tsai CH, Lin FL, Hsiao G, Lai, MJ; Cheng YW, (2021). The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production. Molecules. (26):4359–4378.
    7. Tsai CH, Fang TC, Liao PL, Liao JW, Chan YJ, Cheng YW, Li CH, (2020). The Powdered Root of Eurycoma longifolia Jack Improves Beta-Cell Number and Pancreatic Islet Performance through PDX1 Induction and Shows Antihyperglycemic Activity in db/db Mice. Nutrients. (12):1-16.
    8. Sekar P, Hsiao G, Chen YS, Lin WW, Chan CM, (2023). P2X7 Is Involved in the Mouse Retinal Degeneration via the Coordinated Actions in Different Retinal Cell Types. Antioxidants. (12).
    9. Hsueh PJ, Wang MH, Hsiao CJ, Chen CK, Lin FL, Huang SH, Yen JL, Tsai PH, Kuo YH, Hsiao G, (2021). Ergosta-7,9(11),22-trien-3-ol Alleviates Intracerebral Hemorrhage-Induced Brain Injury and BV-2 Microglial Activation. Molecules. (26):1-18.
    10. Choo Jackson, Liao CH, Tseng CL, Chen JL, Cheng HC, Liang CL, Hank Juo SH, (2023). Inhibition of microRNA-328 Increases Ocular Mucin Expression and Conjunctival Goblet Cells. Biomedicines. (11):1-11.
    11. Chu YA, Fang HW, Wu YY, Tang YJ, Haieh EH, She YZ, Chang CY, Lin IC, Chen YJ, Liu GS, Tseng CL, (2023). Functional Peptide-Loaded Gelatin Nanoparticles as Eyedrops for Cornea Neovascularization Treatment. International Journal of Nanomedicine. Int J Nanomedicine. 23, (18):1413-1431.
    12. Wang JH, Tseng CL, Lin FL, Chen JY, Hsieh EH, Lama S, Chuang YF, Kumar S, Zhu L, McGuinness MY, Hernandez J, Tu L, Wang PY, Liu GS, (2022). Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization. Theranostics. (12):657-674.
    13. Liao CH, Tseng CL, Shiun-LL, Chung-LL, Suh-HJ, (2022). MicroRNA Therapy for Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutic. (38):125-132.
    14. Wang JH, Lin FL, Chen JY, Zhu LX, Chuang YF, Tu LL, Ma CK, Ling DM, Hewitt AW, Tseng CL, Shah MH, Bui BV, Wijngaarden P van, Dusting GJ, Wang PY, Liu GS, (2022). TAK1 blockade as a therapy for retinal neovascularization. Pharmacol Res. (187):1-14.
    15. Tsai CH, Hoang Le Ngoc, Lin CC, Pan LC, Wu CL, Lin IC, Wang PY, Tseng CL*, (2022). Evaluation of Topical and Subconjunctival Injection of Hyaluronic Acid-Coated Nanoparticles for Drug Delivery to Posterior Eye. Pharmaceutics. (14):1-17.
    16. Lin IC, Wang YC, YZ Chen YZ, Tang YJ, Chen KH, Tseng CL, (2022). Dry eye syndrome model established in rabbits via mitomycin C injection in the lacrimal gland. Taiwan Journal of Ophthalmology. Taiwan J Ophthalmol. 4;13(1):34-42.
Top